

±â€Synuclein implicated in Parkinson's disease is pres
including human plasma

FASEB Journal

17, 1-16

DOI: 10.1096/fj.03-0098fje

Citation Report

#	ARTICLE	IF	CITATIONS
1	The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. <i>Human Molecular Genetics</i> , 2004, 13, 123R-126.	1.4	86
2	Glial cell inclusions and the pathogenesis of neurodegenerative diseases. <i>Neuron Glia Biology</i> , 2004, 1, 13-21.	2.0	52
3	A strategy for designing inhibitors of α -synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. <i>FASEB Journal</i> , 2004, 18, 1315-1317.	0.2	165
4	α -Synuclein induces apoptosis by altered expression in human peripheral lymphocytes in Parkinson's disease. <i>FASEB Journal</i> , 2004, 18, 1615-1617.	0.2	81
5	Absence of α -synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. <i>Journal of Neural Transmission</i> , 2005, 112, 1613-1624.	1.4	166
6	Intravesicular Localization and Exocytosis of α -Synuclein and its Aggregates. <i>Journal of Neuroscience</i> , 2005, 25, 6016-6024.	1.7	722
7	Proteolytic Cleavage of Extracellular Secreted α -Synuclein via Matrix Metalloproteinases. <i>Journal of Biological Chemistry</i> , 2005, 280, 25216-25224.	1.6	209
8	Skin and platelet α -synuclein as peripheral biomarkers of Parkinson's disease. <i>Neuroscience Letters</i> , 2005, 381, 294-298.	1.0	101
9	Beta-Amyloid 1 α -42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 200-208.	0.7	114
10	Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. <i>FASEB Journal</i> , 2006, 20, 2000-2008.	0.2	126
11	Detection of oligomeric forms of α -synuclein protein in human plasma as a potential biomarker for Parkinson's disease. <i>FASEB Journal</i> , 2006, 20, 419-425.	0.2	646
12	Decreased α -synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 162-166.	1.0	386
13	Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. <i>Journal of Neurochemistry</i> , 2006, 97, 265-279.	2.1	110
14	The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. <i>Journal of Neural Transmission</i> , 2006, 113, 1435-1439.	1.4	216
16	Inhibitors of α -synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. <i>Experimental Brain Research</i> , 2006, 173, 223-233.	0.7	59
17	Pathophysiology of synuclein aggregation in Lewy body disease. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 188-202.	2.2	67
18	Endogenous α -Synuclein Is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced Excitotoxicity. <i>Journal of Neuroscience</i> , 2006, 26, 7502-7512.	1.7	176
19	Chapter 8 α -Synuclein and Synucleinopathies. <i>Blue Books of Neurology</i> , 2007, 30, 186-215.	0.1	4

#	ARTICLE	IF	CITATIONS
20	Dual localization: Proteins in extracellular and intracellular compartments. <i>Acta Histochemica</i> , 2007, 109, 89-110.	0.9	63
21	Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α -synuclein fibril formation in vitro. <i>Experimental Neurology</i> , 2007, 203, 579-583.	2.0	12
22	Plasma α -synuclein is decreased in subjects with Parkinson's disease. <i>Experimental Neurology</i> , 2007, 204, 583-588.	2.0	140
23	Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. , 2007, , 91-104.		66
24	β -Synuclein and the progression of cancer. <i>FASEB Journal</i> , 2007, 21, 3419-3430.	0.2	94
25	A Macrophage ⁺ Nanozyme Delivery System for Parkinson's Disease. <i>Bioconjugate Chemistry</i> , 2007, 18, 1498-1506.	1.8	177
26	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1481-1484.	2.2	103
27	An investigation into the lipid-binding properties of α -, β - and γ -synucleins in human brain and cerebrospinal fluid. <i>Brain Research</i> , 2007, 1170, 103-111.	1.1	8
28	Tauopathies and synucleinopathies: Do cerebrospinal fluid β -amyloid peptides reflect disease-specific pathogenesis?. <i>Journal of Neural Transmission</i> , 2007, 114, 919-927.	1.4	33
29	Development of α -synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. <i>Acta Neuropathologica</i> , 2007, 114, 231-241.	3.9	358
31	The role of exosomes in the processing of proteins associated with neurodegenerative diseases. <i>European Biophysics Journal</i> , 2008, 37, 323-332.	1.2	220
32	Origins and Effects of Extracellular α -synuclein: Implications in Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2008, 34, 17-22.	1.1	145
33	Microglial phagocytosis is enhanced by monomeric α -synuclein, not aggregated α -synuclein: Implications for Parkinson's disease. <i>Glia</i> , 2008, 56, 1215-1223.	2.5	123
34	Hydrogen exchange of monomeric α -synuclein shows unfolded structure persists at physiological temperature and is independent of molecular crowding in <i>Escherichia coli</i> . <i>Protein Science</i> , 2008, 17, 1434-1445.	3.1	88
35	Analysis of Single, Purified Inclusions as a Novel Approach to Understand Methamphetamine Neurotoxicity. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 186-190.	1.8	5
36	Research in motion: the enigma of Parkinson's disease pathology spread. <i>Nature Reviews Neuroscience</i> , 2008, 9, 741-745.	4.9	296
37	Nitrated α -synuclein ⁺ activated microglial profiling for Parkinson's disease. <i>Journal of Neurochemistry</i> , 2008, 104, 1504-1525.	2.1	195
38	Controlling the mass action of α -synuclein in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2008, 107, 303-316.	2.1	90

#	ARTICLE	IF	CITATIONS
39	Immunological features of α -synuclein in Parkinson's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1820-1829.	1.6	84
40	Nitrated α -Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. <i>PLoS ONE</i> , 2008, 3, e1376.	1.1	311
41	Chapter 6 Molecular and Cellular Biology of Synucleins. <i>International Review of Cell and Molecular Biology</i> , 2008, 270, 225-317.	1.6	90
42	Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood. <i>Neurodegenerative Diseases</i> , 2008, 5, 55-59.	0.8	414
43	Genetic variability in the <i>SNCA</i> gene influences α -synuclein levels in the blood and brain. <i>FASEB Journal</i> , 2008, 22, 1327-1334.	0.2	235
44	α -Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. <i>Neurobiology of Aging</i> , 2008, 29, 739-752.	1.5	202
45	Synuclein activates microglia in a model of Parkinson's disease. <i>Neurobiology of Aging</i> , 2008, 29, 1690-1701.	1.5	397
47	Applications of novel monoclonal antibodies specific for synuclein- β in evaluating its levels in sera and cancer tissues from colorectal cancer patients. <i>Cancer Letters</i> , 2008, 269, 148-158.	3.2	23
48	Direct quantification of CSF α -synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. <i>Experimental Neurology</i> , 2008, 213, 315-325.	2.0	334
49	Clearance and deposition of extracellular α -synuclein aggregates in microglia. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 423-428.	1.0	273
50	Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration. <i>Biomarkers in Medicine</i> , 2008, 2, 465-478.	0.6	19
51	Alpha- and Gamma-Synuclein Proteins Are Present in Cerebrospinal Fluid and Are Increased in Aged Subjects with Neurodegenerative and Vascular Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 32-42.	0.7	38
52	Detection of elevated levels of soluble α -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. <i>Brain</i> , 2008, 132, 1093-1101.	3.7	203
53	Cerebrospinal Fluid α -Synuclein Does Not Discriminate Between Dementia Disorders. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 363-369.	1.2	87
54	Transmissibility of Atypical Scrapie in Ovine Transgenic Mice: Major Effects of Host Prion Protein Expression and Donor Prion Genotype. <i>PLoS ONE</i> , 2009, 4, e7300.	1.1	28
55	Rab11a and HSP90 Regulate Recycling of Extracellular α -Synuclein. <i>Journal of Neuroscience</i> , 2009, 29, 1480-1485.	1.7	128
56	Suppression of Map Kinases Inhibits Microglial Activation and Attenuates Neuronal Cell Death Induced by α -Synuclein Protofibrils. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 897-909.	1.0	76
57	Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element. <i>International Journal of Molecular Sciences</i> , 2009, 10, 1226-1260.	1.8	75

#	ARTICLE	IF	CITATIONS
58	Unique copper-induced oligomers mediate alpha-synuclein toxicity. <i>FASEB Journal</i> , 2009, 23, 2384-2393.	0.2	129
59	Neurochemical biomarkers in the differential diagnosis of movement disorders. <i>Movement Disorders</i> , 2009, 24, 1411-1426.	2.2	37
60	Copper Coordination by Familial Mutants of Parkinson's Disease-Associated α -Synuclein. <i>Applied Magnetic Resonance</i> , 2009, 36, 223-229.	0.6	10
61	Mutant α -Synuclein Overexpression Mediates Early Proinflammatory Activity. <i>Neurotoxicity Research</i> , 2009, 16, 238-254.	1.3	130
62	α -Synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP. <i>Journal of Neurochemistry</i> , 2009, 109, 1483-1496.	2.1	52
63	On the mechanism of internalization of α -synuclein into microglia: roles of ganglioside GM1 and lipid raft. <i>Journal of Neurochemistry</i> , 2009, 110, 400-411.	2.1	116
64	Proteomics in human Parkinson's disease research. <i>Journal of Proteomics</i> , 2009, 73, 10-29.	1.2	98
65	Identification of the amino acid sequence motif of α -synuclein responsible for macrophage activation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 39-43.	1.0	50
66	Effects of intrahippocampal NAC61-95 injections on memory in the rat and attenuation with vitamin E. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 945-951.	2.5	9
67	Cerebrospinal fluid α -synuclein in neurodegenerative disorders: A marker of synapse loss?. <i>Neuroscience Letters</i> , 2009, 450, 332-335.	1.0	194
68	Genomic and proteomic biomarkers for Parkinson disease. <i>Neurology</i> , 2009, 72, S27-31.	1.5	45
69	Functional Protein Delivery into Neurons Using Polymeric Nanoparticles. <i>Journal of Biological Chemistry</i> , 2009, 284, 6972-6981.	1.6	112
70	Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review. <i>CNS Neuroscience and Therapeutics</i> , 2009, 15, 157-182.	1.9	33
73	Are synucleinopathies prion-like disorders?. <i>Lancet Neurology</i> , The, 2010, 9, 1128-1138.	4.9	226
74	Curcumin reduces α -synuclein induced cytotoxicity in Parkinson's disease cell model. <i>BMC Neuroscience</i> , 2010, 11, 57.	0.8	167
75	Oligomeric alpha-synuclein and its role in neuronal death. <i>IUBMB Life</i> , 2010, 62, 334-339.	1.5	44
76	Sensitive and specific detection of α -synuclein in human plasma. <i>Journal of Neuroscience Research</i> , 2010, 88, 2693-2700.	1.3	25
77	Plasma α -synuclein in patients with Parkinson's disease with and without treatment. <i>Movement Disorders</i> , 2010, 25, 489-493.	2.2	93

#	ARTICLE	IF	CITATIONS
78	Identification of ciliary neurotrophic factor receptor α as a mediator of neurotoxicity induced by α -synuclein. <i>Proteomics</i> , 2010, 10, 2138-2150.	1.3	12
79	The sour side of neurodegenerative disorders: the effects of protein glycation. <i>Journal of Pathology</i> , 2010, 221, 13-25.	2.1	138
80	Non-classical exocytosis of α -synuclein is sensitive to folding states and promoted under stress conditions. <i>Journal of Neurochemistry</i> , 2010, 113, 1263-1274.	2.1	241
81	Upregulation of α -synuclein expression in the rat cerebellum in experimental hepatic encephalopathy. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 422-435.	1.8	1
82	Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations. <i>Clinical and Experimental Immunology</i> , 2010, 161, 527-535.	1.1	21
83	Biomarkers: casting the net wide. <i>Nature</i> , 2010, 466, S11-S12.	13.7	26
84	Biomarkers for Cognitive Impairment in Parkinson Disease. <i>Brain Pathology</i> , 2010, 20, 660-671.	2.1	33
85	α -synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010, 22, 321-327.	0.6	20
86	Regulation of Weibel-Palade Body Exocytosis by α -Synuclein in Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 21416-21425.	1.6	34
87	CSF α -synuclein as a diagnostic biomarker for Parkinson disease and related dementias. <i>Neurology</i> , 2010, 75, 1760-1761.	1.5	10
88	α -Synuclein Levels Are Elevated in Cerebrospinal Fluid following Traumatic Brain Injury in Infants and Children: The Effect of Therapeutic Hypothermia. <i>Developmental Neuroscience</i> , 2010, 32, 385-395.	1.0	45
89	Direct Transfer of α -Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies. <i>Journal of Biological Chemistry</i> , 2010, 285, 9262-9272.	1.6	704
90	Progress towards a molecular biomarker for Parkinson disease. <i>Nature Reviews Neurology</i> , 2010, 6, 359-361.	4.9	18
91	Using "omics" to define pathogenesis and biomarkers of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 925-942.	1.4	71
92	Problems associated with fluid biomarkers for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010, 4, 671-681.	0.6	14
93	Cell-Produced α -Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival. <i>Journal of Neuroscience</i> , 2010, 30, 6838-6851.	1.7	913
94	Detection of elevated levels of α -synuclein oligomers in CSF from patients with Parkinson disease. <i>Neurology</i> , 2010, 75, 1766-1770.	1.5	449
95	Quantification of α -synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <i>Biomarkers in Medicine</i> , 2010, 4, 683-699.	0.6	113

#	ARTICLE	IF	CITATIONS
96	Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model. <i>Neurochemistry International</i> , 2010, 57, 16-32.	1.9	24
97	Perivascular nerve fiber α -synuclein regulates contractility of mouse aorta: A link to autonomic dysfunction in Parkinson's disease. <i>Neurochemistry International</i> , 2010, 56, 991-998.	1.9	13
98	Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease. <i>Neuroscience Letters</i> , 2010, 477, 6-10.	1.0	61
99	Bilateral intrahippocampal NAC61 α 95 effects on behavior and moderation with l-NAME treatment. <i>Neuroscience Research</i> , 2010, 66, 213-218.	1.0	2
100	Extracellular neurosin degrades α -synuclein in cultured cells. <i>Neuroscience Research</i> , 2010, 67, 341-346.	1.0	70
101	Altered Ion Channel Formation by the Parkinson's-Disease-Linked E46K Mutant of α -Synuclein Is Corrected by GM3 but Not by GM1 Gangliosides. <i>Journal of Molecular Biology</i> , 2010, 397, 202-218.	2.0	61
102	Behavioural deterioration induced by intrahippocampal NAC61 α 95 injections and attenuation with ibuprofen. <i>Behavioural Brain Research</i> , 2010, 208, 274-277.	1.2	4
103	Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 307-315.	1.1	31
104	CSF α -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 87-95.	1.2	87
105	Metalloproteins and neuronal death. <i>Metallomics</i> , 2010, 2, 186-194.	1.0	30
106	Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 83-102.	1.6	25
107	A novel mechanism of non- $A\beta$ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). <i>Neurochemistry International</i> , 2011, 58, 206-214.	1.9	20
108	Parkinson's disease-associated mutations in α -synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1. <i>Neurochemistry International</i> , 2011, 59, 251-258.	1.9	8
109	Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α -synuclein fibril formation. <i>Neuroscience Letters</i> , 2011, 491, 48-52.	1.0	15
110	Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. <i>Neuroscience Research</i> , 2011, 70, 339-348.	1.0	154
111	Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission. <i>Seminars in Cell and Developmental Biology</i> , 2011, 22, 482-487.	2.3	180
112	Effects of Alpha-Synuclein on Cellular Homeostasis. , 0, , .		0
113	Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-18.	1.1	7

#	ARTICLE	IF	CITATIONS
114	Alpha-Synuclein and the Immune Response in Parkinson's Disease. , 0, , .		1
115	Î±-Synuclein Alters Toll-Like Receptor Expression. <i>Frontiers in Neuroscience</i> , 2011, 5, 80.	1.4	151
116	Î±-Synuclein Expression Selectively Affects Tumorigenesis in Mice Modeling Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e19622.	1.1	30
117	Assessment of Î±-Synuclein Secretion in Mouse and Human Brain Parenchyma. <i>PLoS ONE</i> , 2011, 6, e22225.	1.1	145
118	.ALPHA-Synuclein Aggregation and Transmission Are Enhanced by Leucine-Rich Repeat Kinase 2 in Human Neuroblastoma SH-SY5Y Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2011, 34, 1078-1083.	0.6	43
119	A deadly spread: cellular mechanisms of Î±-synuclein transfer. <i>Cell Death and Differentiation</i> , 2011, 18, 1425-1433.	5.0	131
120	Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. <i>Neurobiology of Disease</i> , 2011, 42, 360-367.	2.1	612
121	Biochemical diagnosis of neurodegenerative diseases gets closer. <i>Lancet Neurology</i> , The, 2011, 10, 203-205.	4.9	3
122	Pathological roles of Î±-synuclein in neurological disorders. <i>Lancet Neurology</i> , The, 2011, 10, 1015-1025.	4.9	328
123	Î±-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. <i>Journal of Clinical Investigation</i> , 2011, 121, 715-725.	3.9	722
124	Glial dysfunction in the pathogenesis of Î±-synucleinopathies: emerging concepts. <i>Acta Neuropathologica</i> , 2011, 121, 675-693.	3.9	164
125	Dopamine and Paraquat Enhance Î±-Synuclein-Induced Alterations in Membrane Conductance. <i>Neurotoxicity Research</i> , 2011, 20, 387-401.	1.3	16
126	Cerebrospinal fluid Tau/Î±-synuclein ratio in Parkinson's disease and degenerative dementias. <i>Movement Disorders</i> , 2011, 26, 1428-1435.	2.2	161
127	Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities. <i>Journal of Neuroscience Methods</i> , 2011, 199, 249-257.	1.3	24
128	Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. <i>Journal of Proteomics</i> , 2011, 74, 371-388.	1.2	129
129	HMGB1 Acts on Microglia Mac1 to Mediate Chronic Neuroinflammation That Drives Progressive Neurodegeneration. <i>Journal of Neuroscience</i> , 2011, 31, 1081-1092.	1.7	305
130	A novel molecular mechanism for nitrated Î±-synuclein-induced cell death. <i>Journal of Molecular Cell Biology</i> , 2011, 3, 239-249.	1.5	76
131	Phosphorylated Î±-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. <i>FASEB Journal</i> , 2011, 25, 4127-4137.	0.2	186

#	ARTICLE	IF	CITATIONS
132	An extracellular mechanism that can explain the neurotoxic effects of β -synuclein aggregates in the brain. <i>Frontiers in Physiology</i> , 2012, 3, 297.	1.3	38
133	Emerging Role for Copper-Bound β -Synuclein in Parkinson's Disease Etiology. , 2012, , 307-338.		1
134	Antibody-Aided Clearance of Extracellular β -Synuclein Prevents Cell-to-Cell Aggregate Transmission. <i>Journal of Neuroscience</i> , 2012, 32, 13454-13469.	1.7	290
135	Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 421-432.	1.5	58
136	Does a prion-like mechanism play a major role in the apparent spread of β -synuclein pathology?. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 48.	3.0	5
137	β -Synuclein: Seeding of β -Synuclein Aggregation and Transmission between Cells. <i>Biochemistry</i> , 2012, 51, 4743-4754.	1.2	79
138	Can Parkinson's disease pathology be propagated from one neuron to another?. <i>Progress in Neurobiology</i> , 2012, 97, 205-219.	2.8	97
139	Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation. <i>Journal of Neuroscience</i> , 2012, 32, 11750-11762.	1.7	228
140	Cross-seeding effects of amyloid β -protein and β -synuclein. <i>Journal of Neurochemistry</i> , 2012, 122, 883-890.	2.1	168
141	Beyond β -synuclein transfer: pathology propagation in Parkinson's disease. <i>Trends in Molecular Medicine</i> , 2012, 18, 248-255.	3.5	69
142	Role of Ser129 phosphorylation of β -synuclein in melanoma cells. <i>Journal of Cell Science</i> , 2013, 126, 696-704.	1.2	32
143	Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity. <i>International Immunopharmacology</i> , 2012, 14, 550-557.	1.7	12
144	From β -synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease. <i>Brain Research</i> , 2012, 1476, 183-202.	1.1	89
145	Alpha-synuclein: from secretion to dysfunction and death. <i>Cell Death and Disease</i> , 2012, 3, e350-e350.	2.7	239
146	Phosphorylated β -synuclein as a potential biomarker for Parkinson's disease and related disorders. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 115-117.	1.5	15
147	The robust electrochemical detection of a Parkinson's disease marker in whole blood sera. <i>Chemical Science</i> , 2012, 3, 3468.	3.7	72
148	Neuroprevention: A new challenge?. <i>Revue Neurologique</i> , 2012, 168, 796-801.	0.6	6
149	β -Synuclein in Parkinson's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009399-a009399.	2.9	958

#	ARTICLE	IF	CITATIONS
150	Increased Neuronal α -Synuclein Pathology Associates with Its Accumulation in Oligodendrocytes in Mice Modeling α -Synucleinopathies. PLoS ONE, 2012, 7, e46817.	1.1	86
151	Characterization of Oligomers of Heterogeneous Size as Precursors of Amyloid Fibril Nucleation of an SH3 Domain: An Experimental Kinetics Study. PLoS ONE, 2012, 7, e49690.	1.1	30
152	α -Synuclein and Anti- α -Synuclein Antibodies in Parkinson's Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls. PLoS ONE, 2012, 7, e52285.	1.1	59
153	α -Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers. PLoS ONE, 2012, 7, e52312.	1.1	45
154	Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	31
155	α -Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	34
156	Pathology of Neurodegenerative Diseases. , 0, , .		3
157	Biochemical premotor biomarkers for Parkinson's disease. Movement Disorders, 2012, 27, 644-650.	2.2	37
158	The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration. Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1, 94-103.	0.7	0
159	Structural characterization of Cu ²⁺ , Ni ²⁺ and Zn ²⁺ binding sites of model peptides associated with neurodegenerative diseases. Coordination Chemistry Reviews, 2012, 256, 352-368.	9.5	100
160	Post mortem cerebrospinal fluid α -synuclein levels are raised in multiple system atrophy and distinguish this from the other α -synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiology of Disease, 2012, 45, 188-195.	2.1	84
161	The role of α -synuclein in neurodegeneration " An update. Translational Neuroscience, 2012, 3, .	0.7	16
162	Variant in the 3' region of SNCA associated with Parkinson's disease and serum α -synuclein levels. Journal of Neurology, 2012, 259, 497-504.	1.8	37
163	Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies. Neurotherapeutics, 2013, 10, 371-382.	2.1	33
164	Neonatal exposure to lipopolysaccharide enhances accumulation of α -synuclein aggregation and dopamine transporter protein expression in the substantia nigra in responses to rotenone challenge in later life. Toxicology, 2013, 308, 96-103.	2.0	16
165	A longitudinal study on α -synuclein in blood plasma as a biomarker for Parkinson's disease. Scientific Reports, 2013, 3, 2540.	1.6	142
166	Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies. Molecular and Cellular Proteomics, 2013, 12, 3543-3558.	2.5	159
167	The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochemical Journal, 2013, 452, 1-17.	1.7	126

#	ARTICLE	IF	CITATIONS
169	Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. <i>Journal of Neurochemistry</i> , 2013, 125, 491-511.	2.1	116
170	Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. <i>Experimental Neurology</i> , 2013, 241, 148-155.	2.0	34
171	Naturally occurring α -synuclein autoantibody levels are lower in patients with Parkinson disease. <i>Neurology</i> , 2013, 80, 169-175.	1.5	108
172	Gender differences in Parkinson's disease: focus on plasma alpha-synuclein. <i>Journal of Neural Transmission</i> , 2013, 120, 1209-1215.	1.4	42
173	Proteolytic clearance of extracellular α -synuclein as a new therapeutic approach against Parkinson disease. <i>Prion</i> , 2013, 7, 121-126.	0.9	20
174	Toxicity of extracellular secreted alpha-synuclein: Its role in nitrosative stress and neurodegeneration. <i>Neurochemistry International</i> , 2013, 62, 776-783.	1.9	29
175	The secreted oligomeric form of α -synuclein affects multiple steps of membrane trafficking. <i>FEBS Letters</i> , 2013, 587, 452-459.	1.3	25
176	α -Synuclein: The Long Distance Runner. <i>Brain Pathology</i> , 2013, 23, 350-357.	2.1	107
177	alpha-Synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. <i>Journal of Molecular Medicine</i> , 2013, 91, 693-703.	1.7	55
178	Activity-dependent secretion of alpha-synuclein by enteric neurons. <i>Journal of Neurochemistry</i> , 2013, 125, 512-517.	2.1	77
179	The Driving Force of Alpha-Synuclein Insertion and Amyloid Channel Formation in the Plasma Membrane of Neural Cells: Key Role of Ganglioside- and Cholesterol-Binding Domains. <i>Advances in Experimental Medicine and Biology</i> , 2013, 991, 15-26.	0.8	63
180	An Update on CSF Biomarkers of Parkinson's Disease. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2013, , 161-184.	0.6	5
181	Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. <i>Journal of Parkinson's Disease</i> , 2013, 3, 415-459.	1.5	68
182	May the Evaluation of Nitrosative Stress Through Selective Increase of 3-Nitrotyrosine Proteins Other Than Nitroalbumin and Dominant Tyrosine-125/136 Nitrosylation of Serum α -Synuclein Serve for Diagnosis of Sporadic Parkinson's Disease?. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 912-918.	2.5	38
184	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
186	Role of Oxidative Stress in Parkinson's Disease. <i>Experimental Neurobiology</i> , 2013, 22, 11-17.	0.7	518
187	Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-20.	3.3	30
188	Alpha-Synuclein Function and Dysfunction on Cellular Membranes. <i>Experimental Neurobiology</i> , 2014, 23, 292-313.	0.7	179

#	ARTICLE	IF	CITATIONS
189	Protein Transmission, Seeding and Degradation: Key Steps for α -Synuclein Prion-Like Propagation. <i>Experimental Neurobiology</i> , 2014, 23, 324-336.	0.7	45
190	Immunotherapy targeting α -synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. <i>Immunotherapy</i> , 2014, 6, 141-153.	1.0	48
191	When amyloids become prions. <i>Prion</i> , 2014, 8, 233-239.	0.9	13
192	Cerebrospinal fluid α -synuclein in the differential diagnosis of parkinsonian syndromes. <i>Future Neurology</i> , 2014, 9, 525-532.	0.9	8
193	Biomarkers in biological fluids for dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 72.	3.0	28
194	Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. <i>PLoS Genetics</i> , 2014, 10, e1004741.	1.5	168
195	Increase of the plasma α -synuclein levels in patients with multiple system atrophy. <i>Movement Disorders</i> , 2014, 29, 375-379.	2.2	20
196	Biomarkers of Parkinson's disease. , 2014, , 817-831.		0
197	Proteomics as a new paradigm to tackle Parkinson's disease research challenges. <i>Translational Proteomics</i> , 2014, 4-5, 1-17.	1.2	11
198	Elevated levels of cerebrospinal fluid α -synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 248.	1.7	59
199	Mechanisms of action of brain insulin against neurodegenerative diseases. <i>Journal of Neural Transmission</i> , 2014, 121, 611-626.	1.4	20
200	Blood-based biomarkers for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S99-S103.	1.1	117
201	Oxidative Stress Promotes Uptake, Accumulation, and Oligomerization of Extracellular α -Synuclein in Oligodendrocytes. <i>Journal of Molecular Neuroscience</i> , 2014, 52, 339-352.	1.1	40
202	A porous silicon immunoassay platform for fluorometric determination of α -synuclein in human cerebrospinal fluid. <i>Mikrochimica Acta</i> , 2014, 181, 1143-1149.	2.5	7
203	The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α -synuclein, and enhances its secretion and nuclear localization in cells. <i>Human Molecular Genetics</i> , 2014, 23, 4491-4509.	1.4	194
204	Increased α -synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2014, 261, 1203-1209.	1.8	34
205	Cerebrospinal fluid α -synuclein levels in Parkinson's disease – changed or unchanged?. <i>European Journal of Neurology</i> , 2014, 21, 365-367.	1.7	14
206	The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. <i>Neurobiology of Disease</i> , 2014, 63, 1-11.	2.1	97

#	ARTICLE	IF	CITATIONS
207	Systems Approach to Neurodegenerative Disease Biomarker Discovery. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 457-481.	4.2	45
208	Extracellular α -synuclein a novel and crucial factor in Lewy body diseases. <i>Nature Reviews Neurology</i> , 2014, 10, 92-98.	4.9	255
209	ATP13A2/PARK9 Regulates Secretion of Exosomes and α -Synuclein. <i>Journal of Neuroscience</i> , 2014, 34, 15281-15287.	1.7	148
210	Alpha synuclein is transported into and out of the brain by the blood-brain barrier. <i>Peptides</i> , 2014, 62, 197-202.	1.2	138
211	The small GTPase Rab11 co-localizes with α -synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. <i>Human Molecular Genetics</i> , 2014, 23, 6732-6745.	1.4	73
212	Plasma exosomal α -synuclein is likely CNS-derived and increased in Parkinson's disease. <i>Acta Neuropathologica</i> , 2014, 128, 639-650.	3.9	504
213	Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson's Disease. <i>Drugs and Aging</i> , 2014, 31, 239-261.	1.3	25
214	Exogenous α -Synuclein Decreases Raft Partitioning of Cav2.2 Channels Inducing Dopamine Release. <i>Journal of Neuroscience</i> , 2014, 34, 10603-10615.	1.7	53
215	Structural Characterization of Heparin-induced Glyceraldehyde-3-phosphate Dehydrogenase Protofibrils Preventing α -Synuclein Oligomeric Species Toxicity. <i>Journal of Biological Chemistry</i> , 2014, 289, 13838-13850.	1.6	31
216	What can biomarkers tell us about cognition in Parkinson's disease?. <i>Movement Disorders</i> , 2014, 29, 622-633.	2.2	61
217	Alpha-synuclein spreading in Parkinson's disease. <i>Frontiers in Neuroanatomy</i> , 2014, 8, 159.	0.9	148
218	Protein phosphorylation in neurodegeneration: friend or foe?. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 42.	1.4	203
219	Cofilin 1 activation prevents the defects in axon elongation and guidance induced by extracellular alpha-synuclein. <i>Scientific Reports</i> , 2015, 5, 16524.	1.6	36
220	Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis. <i>Journal of Neurochemistry</i> , 2015, 134, 748-755.	2.1	12
221	Electroacupuncture remediates glial dysfunction and ameliorates neurodegeneration in the astrocytic α -synuclein mutant mouse model. <i>Journal of Neuroinflammation</i> , 2015, 12, 103.	3.1	25
222	Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. <i>Journal of Parkinson's Disease</i> , 2015, 5, 413-424.	1.5	69
223	Disease-modifying therapeutic directions for Lewy-Body dementias. <i>Frontiers in Neuroscience</i> , 2015, 9, 293.	1.4	23
224	Alpha-Synuclein Levels in Blood Plasma Decline with Healthy Aging. <i>PLoS ONE</i> , 2015, 10, e0123444.	1.1	42

#	ARTICLE	IF	CITATIONS
225	The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis. <i>Parkinson's Disease</i> , 2015, 2015, 1-11.	0.6	45
226	Could α -Synuclein Amyloid-Like Aggregates Trigger a Prionic Neuronal Invasion?. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	10
227	The Interplay between Alpha-Synuclein Clearance and Spreading. <i>Biomolecules</i> , 2015, 5, 435-471.	1.8	79
228	The N-Terminus of α -Synuclein Forms Cu(II)-Bridged Oligomers. <i>Chemistry - A European Journal</i> , 2015, 21, 7111-7118.	1.7	21
229	Mechanisms of Alpha-Synuclein Action on Neurotransmission: Cell-Autonomous and Non-Cell Autonomous Role. <i>Biomolecules</i> , 2015, 5, 865-892.	1.8	37
230	Detection of α -synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. <i>Neuroscience Letters</i> , 2015, 599, 115-119.	1.0	121
231	Extracellular α -synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. <i>Journal of Neurochemistry</i> , 2015, 132, 731-741.	2.1	71
232	Molecular Determinants of α -Synuclein Mutants' Oligomerization and Membrane Interactions. <i>ACS Chemical Neuroscience</i> , 2015, 6, 403-416.	1.7	38
233	Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α -Synuclein for Assessing Antiparkinson Agents. <i>Molecular Neurobiology</i> , 2015, 52, 226-235.	1.9	6
234	TDP-43 activates microglia through NF- κ B and NLRP3 inflammasome. <i>Experimental Neurology</i> , 2015, 273, 24-35.	2.0	174
235	Animal models for prion-like diseases. <i>Virus Research</i> , 2015, 207, 5-24.	1.1	10
236	α -Synuclein and β -Amyloid form a Bridged Copper Complex. <i>Applied Magnetic Resonance</i> , 2015, 46, 1041-1052.	0.6	7
238	Parkinson disease with REM sleep behavior disorder. <i>Neurology</i> , 2015, 84, 888-894.	1.5	77
239	Prion 2015 Poster Abstracts. <i>Prion</i> , 2015, 9, S11-S99.	0.9	4
240	Bent out of shape: α -Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. <i>FEBS Letters</i> , 2015, 589, 3749-3759.	1.3	50
241	Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. <i>Biomedicine and Pharmacotherapy</i> , 2015, 74, 101-110.	2.5	683
242	A cell culture model for monitoring α -synuclein cell-to-cell transfer. <i>Neurobiology of Disease</i> , 2015, 77, 266-275.	2.1	72
243	A Novel Microfluidic Cell Co-culture Platform for the Study of the Molecular Mechanisms of Parkinson's Disease and Other Synucleinopathies. <i>Frontiers in Neuroscience</i> , 2016, 10, 511.	1.4	43

#	ARTICLE	IF	CITATIONS
244	Key Points Concerning Amyloid Infectivity and Prion-Like Neuronal Invasion. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 29.	1.4	19
245	Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 173.	1.8	196
246	Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant. <i>PLoS ONE</i> , 2016, 11, e0162717.	1.1	117
247	"Synuclein in Neurodegeneration" A Good Protein that may go Bad. <i>Brain Pathology</i> , 2016, 26, 387-388.	2.1	0
248	Alpha-synuclein propagation: New insights from animal models. <i>Movement Disorders</i> , 2016, 31, 161-168.	2.2	100
249	Structural basis for the dissociation of α -synuclein fibrils triggered by pressure perturbation of the hydrophobic core. <i>Scientific Reports</i> , 2016, 6, 37990.	1.6	35
250	How strong is the evidence that Parkinson's disease is a prion disorder?. <i>Current Opinion in Neurology</i> , 2016, 29, 459-466.	1.8	59
251	Alpha-Synuclein as a Diagnostic Biomarker for Parkinson's Disease. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 215-234.	0.1	1
252	Alpha-synuclein-based models of Parkinson's disease. <i>Revue Neurologique</i> , 2016, 172, 371-378.	0.6	38
253	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3126-3138.	2.5	92
254	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 117-123.	3.0	8
255	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. <i>Movement Disorders</i> , 2016, 31, 848-860.	2.2	52
256	Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. <i>Journal of Neurochemistry</i> , 2016, 139, 275-289.	2.1	77
257	Review: Sporadic Parkinson's disease: development and distribution of α -synuclein pathology. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 33-50.	1.8	309
258	Impairment of PDGF-induced chemotaxis by extracellular α -synuclein through selective inhibition of Rac1 activation. <i>Scientific Reports</i> , 2016, 6, 37810.	1.6	9
259	Mechanisms for cell-to-cell propagation no longer lag behind. <i>Movement Disorders</i> , 2016, 31, 1798-1799.	2.2	2
260	Total α -synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 7669-7677.	1.9	22
261	The neural chaperone proSAAS blocks α -synuclein fibrillation and neurotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4708-15.	3.3	38

#	ARTICLE	IF	CITATIONS
262	Exosomes in the Pathology of Neurodegenerative Diseases. <i>Journal of Biological Chemistry</i> , 2016, 291, 26589-26597.	1.6	190
263	Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. <i>BMC Neurology</i> , 2016, 16, 180.	0.8	22
264	Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. <i>Journal of Nanobiotechnology</i> , 2016, 14, 41.	4.2	59
265	Animal modeling an oligodendroglialopathy " multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 12.	2.4	16
266	Protein Misfolding and Aggregation: Implications for Mitochondrial Dysfunction and Neurodegeneration. , 2016, , 241-253.		1
267	Induction of α -synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 481-494.	3.7	349
268	Value of cerebrospinal fluid α -synuclein species as biomarker in Parkinson's diagnosis and prognosis. <i>Biomarkers in Medicine</i> , 2016, 10, 35-49.	0.6	51
269	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2016, 17, 251-260.	4.9	251
270	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	2.1	58
271	Glucocerebrosidase and parkinsonism: lessons to learn. <i>Journal of Neurology</i> , 2016, 263, 1033-1044.	1.8	6
272	Decreased Toll-Like Receptor 2 and Toll-Like Receptor 7/8-Induced Cytokines in Parkinson's Disease Patients. <i>NeuroImmunoModulation</i> , 2016, 23, 58-66.	0.9	28
273	Effects of different isoforms of apoE on aggregation of the α -synuclein protein implicated in Parkinson's disease. <i>Neuroscience Letters</i> , 2016, 618, 146-151.	1.0	28
274	Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. <i>Molecular Therapy</i> , 2016, 24, 746-758.	3.7	38
275	The utility of α -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , 2016, 10, 19-34.	0.6	86
276	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. <i>Progress in Neurobiology</i> , 2017, 155, 171-193.	2.8	137
277	Traffic jams and the complex role of α -Synuclein aggregation in Parkinson disease. <i>Small GTPases</i> , 2017, 8, 78-84.	0.7	15
278	Alpha-Synuclein in Cerebrospinal Fluid. , 2017, , 171-192.		0
279	Lewy body dementia. , 2017, , 175-198.		2

#	ARTICLE	IF	CITATIONS
280	In vitro α -synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. <i>Neurobiology of Disease</i> , 2017, 103, 101-112.	2.1	96
281	Plasma α -synuclein predicts cognitive decline in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 818-824.	0.9	128
282	AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson's disease diagnosis. <i>Protein and Cell</i> , 2017, 8, 696-700.	4.8	9
283	Microglia P2Y6 receptor is related to Parkinson's disease through neuroinflammatory process. <i>Journal of Neuroinflammation</i> , 2017, 14, 38.	3.1	58
284	Extracellular α -synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β 2-arrestin signal intact. <i>Scientific Reports</i> , 2017, 7, 44248.	1.6	13
285	The Transcellular Propagation and Intracellular Trafficking of α -Synuclein. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024380.	2.9	28
287	α -Synuclein Oligomers: A Study in Diversity. <i>Israel Journal of Chemistry</i> , 2017, 57, 699-723.	1.0	16
288	Role of neurotoxicants and traumatic brain injury in α -synuclein protein misfolding and aggregation. <i>Brain Research Bulletin</i> , 2017, 133, 60-70.	1.4	47
289	Structural Characteristics of α -Synuclein Oligomers. <i>International Review of Cell and Molecular Biology</i> , 2017, 329, 79-143.	1.6	95
290	Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 13713.	1.6	79
291	The Oligomer Hypothesis in α -Synucleinopathy. <i>Neurochemical Research</i> , 2017, 42, 3362-3371.	1.6	53
292	α -Synuclein Interacts with Lipoproteins in Plasma. <i>Journal of Molecular Neuroscience</i> , 2017, 63, 165-172.	1.1	32
293	Comparison of α -Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2722-2733.	1.7	52
294	Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7929-E7938.	3.3	125
295	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
296	Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α -synuclein targeted disease modification. <i>Experimental Neurology</i> , 2017, 298, 172-179.	2.0	45
297	Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview. <i>Advances in Neurobiology</i> , 2017, 15, 55-92.	1.3	2
298	Post translational changes to α -synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2017, 12, 45.	4.4	61

#	ARTICLE	IF	CITATIONS
299	Pathological α -synuclein exacerbates the progression of Parkinson's disease through microglial activation. <i>Toxicology Letters</i> , 2017, 265, 30-37.	0.4	119
300	Disease-Toxicant Interactions in Parkinson's Disease Neuropathology. <i>Neurochemical Research</i> , 2017, 42, 1772-1786.	1.6	15
301	Antibodies against the C-terminus of α -synuclein modulate its fibrillation. <i>Biophysical Chemistry</i> , 2017, 220, 34-41.	1.5	29
302	Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications. <i>Biological Chemistry</i> , 2017, 398, 77-100.	1.2	50
303	Neurodegenerative Disorders. , 2017, , 1-16.		18
304	Rab GTPases: The Key Players in the Molecular Pathway of Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 81.	1.8	59
305	Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach. <i>Frontiers in Neuroscience</i> , 2017, 11, 3.	1.4	44
306	Apolipoprotein E μ 4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2017, 11, 712.	1.4	16
307	Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 276.	1.4	87
308	The Contribution of α -Synuclein Spreading to Parkinson's Disease Synaptopathy. <i>Neural Plasticity</i> , 2017, 2017, 1-15.	1.0	70
309	Running wheel exercise reduces α -synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0190160.	1.1	65
310	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. <i>Brain, Behavior, and Immunity</i> , 2018, 69, 591-602.	2.0	55
311	The concept of alpha-synuclein as a prion-like protein: ten years after. <i>Cell and Tissue Research</i> , 2018, 373, 161-173.	1.5	138
312	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018, 33, 528-536.	2.2	17
314	Extracellular α -synuclein drives sphingosine 1-phosphate receptor subtype 1 out of lipid rafts, leading to impaired inhibitory G-protein signaling. <i>Journal of Biological Chemistry</i> , 2018, 293, 8208-8216.	1.6	42
315	Release and uptake of pathologic alpha-synuclein. <i>Cell and Tissue Research</i> , 2018, 373, 175-182.	1.5	57
316	The relation between plasma α -synuclein level and clinical symptoms or signs of Parkinson's disease. <i>Neurologia i Neurochirurgia Polska</i> , 2018, 52, 243-251.	0.6	33
317	The Potential Role of Toll-Like Receptor 4 in Mediating Dopaminergic Cell Loss and Alpha-Synuclein Expression in the Acute MPTP Mouse Model of Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 611-618.	1.1	26

#	ARTICLE	IF	CITATIONS
318	Cell Biology and Pathophysiology of α -Synuclein. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a024091.	2.9	353
319	Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. Neurobiology of Disease, 2018, 109, 219-225.	2.1	80
320	Critical appraisal of pathology transmission in the α -synuclein fibril model of Lewy body disorders. Experimental Neurology, 2018, 299, 172-196.	2.0	33
321	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
322	Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α -synuclein in neurons. Neurobiology of Disease, 2018, 111, 26-35.	2.1	108
323	Autophagy inhibition promotes SNCA/ α -synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. Autophagy, 2018, 14, 98-119.	4.3	193
324	Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. Neuroscience Letters, 2018, 672, 145-149.	1.0	35
325	The PMR1 pump in alpha-synuclein toxicity and neurodegeneration. Neuroscience Letters, 2018, 663, 66-71.	1.0	5
326	α -Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Movement Disorders, 2018, 33, 1724-1733.	2.2	79
327	α -Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models. ASN Neuro, 2018, 10, 175909141881258.	1.5	12
328	Significant Changes in Plasma Alpha-Synuclein and Beta-Synuclein Levels in Male Children with Autism Spectrum Disorder. BioMed Research International, 2018, 2018, 1-7.	0.9	20
329	α -Synuclein concentration increases over time in plasma supernatant of single donor platelets. European Journal of Haematology, 2018, 101, 630-634.	1.1	6
330	Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. International Journal of Molecular Sciences, 2018, 19, 336.	1.8	51
331	A new model to study cell-to-cell transfer of α -Synuclein in vivo. Biochemical and Biophysical Research Communications, 2018, 503, 1385-1393.	1.0	7
332	Prion-like propagation of pathology in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 321-335.	1.0	58
333	Metallomics Applied to the Study of Neurodegenerative and Mental Diseases. Advances in Experimental Medicine and Biology, 2018, 1055, 21-37.	0.8	11
334	A Genome-Wide Association Study of α -Synuclein Levels in Cerebrospinal Fluid. Neurotoxicity Research, 2019, 35, 41-48.	1.3	7
335	What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?. Journal of Parkinson's Disease, 2019, 9, 467-488.	1.5	10

#	ARTICLE	IF	CITATIONS
336	Manganese-Induced Neurotoxicity: New Insights Into the Triad of Protein Misfolding, Mitochondrial Impairment, and Neuroinflammation. <i>Frontiers in Neuroscience</i> , 2019, 13, 654.	1.4	167
337	Initiation and Transmission of α -Synuclein Pathology in Parkinson's Disease. <i>Neurochemical Research</i> , 2019, 44, 2685-2694.	1.6	6
338	Alpha synuclein in hematopoiesis and immunity. <i>Heliyon</i> , 2019, 5, e02590.	1.4	40
339	Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay. <i>Frontiers in Neuroscience</i> , 2019, 13, 889.	1.4	25
340	Immunotherapy in Parkinson's disease: Current status and future directions. <i>Neurobiology of Disease</i> , 2019, 132, 104587.	2.1	41
341	Integrins: A missing link in synuclein's pathogenic mechanism. <i>Journal of Neuroscience Research</i> , 2019, 97, 539-542.	1.3	4
342	Detection of Parkinson's Disease through the Peptoid Recognizing α -Synuclein in Serum. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1204-1208.	1.7	14
343	α -Synuclein pathology in Parkinson's disease and related α -synucleinopathies. <i>Neuroscience Letters</i> , 2019, 709, 134316.	1.0	177
344	Spreading of α -Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 107.	1.4	79
345	Antibodies against alpha-synuclein: tools and therapies. <i>Journal of Neurochemistry</i> , 2019, 150, 612-625.	2.1	53
346	Interferon- β Potentiates α -Synuclein-induced Neurotoxicity Linked to Toll-like Receptors 2 and 3 and Tumor Necrosis Factor- α in Murine Astrocytes. <i>Molecular Neurobiology</i> , 2019, 56, 7664-7679.	1.9	15
347	<i>In vitro</i> models of synucleinopathies: informing on molecular mechanisms and protective strategies. <i>Journal of Neurochemistry</i> , 2019, 150, 535-565.	2.1	33
348	Neurodegeneration meets immunology – A chemical biology perspective. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1911-1924.	1.4	0
349	Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α -synuclein. <i>Science Signaling</i> , 2019, 12, .	1.6	129
350	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 573-586.	4.9	393
351	Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. <i>Brain</i> , 2019, 142, 1365-1385.	3.7	82
352	Biomarkers of Parkinson's Disease. , 2019, , 895-909.		0
353	Physiological, molecular and genetic aspects of alpha-synuclein and its correlation with high alcohol consumption. <i>Revista Facultad De Medicina</i> , 2019, 67, 315-322.	0.0	0

#	ARTICLE	IF	CITATIONS
354	Cholesterol Metabolism in the Brain and Its Association with Parkinson's Disease. <i>Experimental Neurobiology</i> , 2019, 28, 554-567.	0.7	95
355	Simultaneous quantification of tau and α -synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls. <i>Analyst</i> , 2019, 144, 6342-6351.	1.7	13
356	Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice. <i>Journal of Neuroinflammation</i> , 2019, 16, 250.	3.1	85
357	Exosomal Transport and Progression of Neurodegeneration in Amyotrophic Lateral Sclerosis. <i>Neurochemical Journal</i> , 2019, 13, 229-239.	0.2	2
358	Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience. <i>Frontiers in Medicine</i> , 2019, 6, 268.	1.2	11
359	Cerebrospinal fluid biomarker for Parkinson's disease: An overview. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 60-66.	1.0	32
360	Increased Serum Levels of α -Synuclein in Patients With Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 280-286.	0.6	18
361	Alpha Synuclein and Parkinson's Disease. , 2019, , 1-14.		3
362	Correlation between Cellular Uptake and Cytotoxicity of Fragmented α -Synuclein Amyloid Fibrils Suggests Intracellular Basis for Toxicity. <i>ACS Chemical Neuroscience</i> , 2020, 11, 233-241.	1.7	26
363	NK cells clear α -synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α -synucleinopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1762-1771.	3.3	77
364	Characterization of novel conformation-selective α -synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104712.	2.1	31
365	From Synaptic Protein to Prion: The Long and Controversial Journey of α -Synuclein. <i>Frontiers in Synaptic Neuroscience</i> , 2020, 12, 584536.	1.3	20
366	Metal ions shape α -synuclein. <i>Scientific Reports</i> , 2020, 10, 16293.	1.6	55
367	Expresi3n de alfa sinucle3na en sangre y su relaci3n con el estre3imiento cr3nico en poblaci3n residente en Bogot3, D.C., con problemas de consumo de alcohol. <i>Biomedica</i> , 2020, 40, 309-321.	0.3	1
368	Extracellular Vesicles in Alzheimer's and Parkinson's Disease: Small Entities with Large Consequences. <i>Cells</i> , 2020, 9, 2485.	1.8	36
369	Cerebrospinal fluid α -synuclein predicts neurodegeneration and clinical progression in non-demented elders. <i>Translational Neurodegeneration</i> , 2020, 9, 41.	3.6	7
370	Plasma Total α -Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 401-409.	0.7	11
371	Parkinson's: A Disease of Aberrant Vesicle Trafficking. <i>Annual Review of Cell and Developmental Biology</i> , 2020, 36, 237-264.	4.0	54

#	ARTICLE	IF	CITATIONS
372	Î±-Synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?. <i>Neuroscientist</i> , 2021, 27, 107385842094318.	2.6	5
373	Ubiquitin, Autophagy and Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 2022.	1.8	44
374	In Search of Effective Treatments Targeting Î±-Synuclein Toxicity in Synucleinopathies: Pros and Cons. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 559791.	1.8	14
375	Î±-Synuclein promotes IAPP fibril formation in vitro and Î²-cell amyloid formation in vivo in mice. <i>Scientific Reports</i> , 2020, 10, 20438.	1.6	25
376	Molecular events underlying the cell-to-cell transmission of Î±-synuclein. <i>FEBS Journal</i> , 2021, 288, 6593-6602.	2.2	27
377	Fibroblast growth factor 21 and autophagy: A complex interplay in Parkinson disease. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110145.	2.5	18
378	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. <i>Brain</i> , 2020, 143, 1462-1475.	3.7	135
379	Interfaces Determine the Fate of Seeded Î±-Synuclein Aggregation. <i>Advanced Materials Interfaces</i> , 2020, 7, 2000446.	1.9	7
380	Plasma Levels of Î±-Synuclein, AÎ²-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 112.	1.7	30
381	The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease. <i>Biomolecules</i> , 2020, 10, 912.	1.8	18
382	Initiation and propagation of Î±-synuclein aggregation in the nervous system. <i>Molecular Neurodegeneration</i> , 2020, 15, 19.	4.4	156
383	A nanospherical conjugated microporous polymer-graphene nanosheets modified molecularly imprinted electrochemical sensor for high sensitivity detection of Î±-Synuclein. <i>Journal of Electroanalytical Chemistry</i> , 2020, 862, 113994.	1.9	42
384	Overexpression of alpha-synuclein promotes both cell proliferation and cell toxicity in human SH-SY5Y neuroblastoma cells. <i>Journal of Advanced Research</i> , 2020, 23, 37-45.	4.4	32
385	Modeling Parkinson's Disease With the Alpha-Synuclein Protein. <i>Frontiers in Pharmacology</i> , 2020, 11, 356.	1.6	195
386	Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 720-729.	0.9	148
387	Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more. <i>Revue Neurologique</i> , 2021, 177, 260-271.	0.6	14
388	Low serum Î±-SYNUCLEIN and oligomer Î±-SYNUCLEIN levels in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 350, 577432.	1.1	4
389	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. <i>Progress in Molecular Biology and Translational Science</i> , 2021, 177, 175-202.	0.9	21

#	ARTICLE	IF	CITATIONS
390	Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. <i>Journal of Parkinson's Disease</i> , 2021, 11, 71-92.	1.5	21
391	Retina as a Model to Study In Vivo Transmission of α -Synuclein in the A53T Mouse Model of Parkinson's Disease. <i>Methods in Molecular Biology</i> , 2021, 2224, 75-85.	0.4	4
392	Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?. <i>Frontiers in Neuroscience</i> , 2020, 14, 580311.	1.4	15
393	Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. <i>Cells</i> , 2021, 10, 375.	1.8	54
394	Biomarkers and the Role of α -Synuclein in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 645996.	1.7	13
395	Prionopathies and Prionlike Protein Aberrations in Neurodegenerative Diseases. <i>Neurographics</i> , 2021, 11, 127-148.	0.0	0
396	Inflammatory Responses to Monomeric and Aggregated α -Synuclein in Peripheral Blood of Parkinson Disease Patients. <i>Frontiers in Neuroscience</i> , 2021, 15, 639646.	1.4	23
399	Decreased Exosomal Acetylcholinesterase Activity in the Plasma of Patients With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 665400.	1.7	12
400	Neurons and Glia Interplay in α -Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4994.	1.8	28
402	Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 636139.	1.1	26
403	Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6517.	1.8	38
404	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1761-1772.	1.5	15
405	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	2.5	74
406	Neuroprotective Effects of Trehalose and Sodium Butyrate on Preformed Fibrillar Form of α -Synuclein-Induced Rat Model of Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2643-2660.	1.7	20
407	Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration. <i>Current Neuropharmacology</i> , 2022, 20, 1450-1478.	1.4	5
408	Plasma total tau predicts executive dysfunction in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 30-37.	1.0	10
409	Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. <i>Cell</i> , 2021, 184, 5089-5106.e21.	13.5	158
410	Is Multiple System Atrophy a Prion-like Disorder?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10093.	1.8	12

#	ARTICLE	IF	CITATIONS
411	Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct α -Synuclein Assemblies. <i>Journal of Immunology</i> , 2021, 207, 2143-2154.	0.4	53
412	Transcutaneous vagus nerve stimulation (tVNS) as a potential therapeutic application for neurodegenerative disorders – A focus on dysautonomia in Parkinson's disease. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2021, 235, 102858.	1.4	2
414	The Interplay Between Proteostasis Systems and Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1233, 223-236.	0.8	6
415	Single-Molecule Characterization of the Interactions between Extracellular Chaperones and Toxic α -Synuclein Oligomers. <i>Cell Reports</i> , 2018, 23, 3492-3500.	2.9	59
416	Phosphorylated Alpha-Synuclein in Red Blood Cells as a Potential Diagnostic Biomarker for Multiple System Atrophy: A Pilot Study. <i>Parkinson's Disease</i> , 2020, 2020, 1-12.	0.6	9
417	Formation of Toxic Oligomeric α -Synuclein Species in Living Cells. <i>PLoS ONE</i> , 2008, 3, e1867.	1.1	354
418	Glial Innate Immunity Generated by Non-Aggregated Alpha-Synuclein in Mouse: Differences between Wild-type and Parkinson's Disease-Linked Mutants. <i>PLoS ONE</i> , 2010, 5, e13481.	1.1	89
419	Inhibiting α -Synuclein Oligomerization by Stable Cell-Penetrating α -Synuclein Fragments Recovers Phenotype of Parkinson's Disease Model Flies. <i>PLoS ONE</i> , 2010, 5, e13863.	1.1	92
420	α -Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients. <i>PLoS ONE</i> , 2011, 6, e18513.	1.1	146
421	PrPSc-Specific Antibodies with the Ability to Immunodetect Prion Oligomers. <i>PLoS ONE</i> , 2011, 6, e19998.	1.1	21
422	The AAA-ATPase VPS4 Regulates Extracellular Secretion and Lysosomal Targeting of α -Synuclein. <i>PLoS ONE</i> , 2011, 6, e29460.	1.1	120
423	Triggering of Inflammasome by Aggregated α -Synuclein, an Inflammatory Response in Synucleinopathies. <i>PLoS ONE</i> , 2013, 8, e55375.	1.1	465
424	Preconditioning of Microglia by α -Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation. <i>PLoS ONE</i> , 2013, 8, e79160.	1.1	92
425	Direct Observation of α -Synuclein Amyloid Aggregates in Endocytic Vesicles of Neuroblastoma Cells. <i>PLoS ONE</i> , 2016, 11, e0153020.	1.1	34
426	Emerging candidate biomarkers for Parkinson's disease: a review. , 2014, 5, 27-34.		26
427	Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?. , 2014, 5, 63-75.		33
428	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α -syn) oligomerization and secretion. <i>Aging</i> , 2017, 9, 1677-1697.	1.4	7
429	Chronic exposure to cerebrospinal fluid of multiple system atrophy in neuroblastoma and glioblastoma cells induces cytotoxicity via ER stress and autophagy activation. <i>Oncotarget</i> , 2015, 6, 13278-13294.	0.8	6

#	ARTICLE	IF	CITATIONS
430	Modulating the Amyloidogenesis of α -Synuclein. <i>Current Neuropharmacology</i> , 2016, 14, 226-237.	1.4	7
431	When amyloids become prions. <i>Prion</i> , 2014, 8, .	0.9	2
432	Alpha-synuclein truncation and disease. <i>Health</i> , 2012, 04, 1167-1177.	0.1	6
433	Topographical Propagation of α -synuclein Pathology in Parkinson's Disease: Phenomenology and Hypothetical Mechanism. <i>Experimental Neurobiology</i> , 2009, 18, 19.	0.7	1
434	Towards New Therapies for Parkinson's Disease. , 2011, , .		10
435	Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery. <i>Biomolecules</i> , 2021, 11, 1508.	1.8	59
436	Examining the Toxicity of α -Synuclein in Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 1126.	1.1	4
437	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. <i>Pharmacological Reviews</i> , 2021, 73, 1204-1268.	7.1	11
438	Purification and Quantification of Neural α -synuclein. , 2008, , 559-573.		1
439	CFS Biomarkers in Parkinson's Disease. , 0, , .		0
440	Brain Damage - Bridging Between Basic Research and Clinics. , 2012, , .		9
441	Cardiovascular Proteomic Analysis. , 2013, , 81-98.		0
442	Autophagy. , 2015, , 13-19.e2.		0
443	Extracellular α -Synuclein as a Target for Immunotherapy. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 73-83.	0.1	0
444	Laboratory Biomarkers of Early Diagnosis of Parkinson's Disease. <i>International Neurological Journal</i> , 2016, .	0.2	2
445	SNARE Proteins Mediate α -Synuclein Secretion via Multiple Vesicular Pathways. <i>Molecular Neurobiology</i> , 2022, 59, 405-419.	1.9	9
446	Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. <i>MABs</i> , 2021, 13, 1994690.	2.6	10
447	Alpha-synuclein and neuroinflammation in Parkinson's disease. , 2020, , 431-446.		1

#	ARTICLE	IF	CITATIONS
448	Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 769506.	1.7	19
449	Alpha-Synuclein, cyclooxygenase-2 and prostaglandins-EP2 receptors as neuroinflammatory biomarkers of autism spectrum disorders: Use of combined ROC curves to increase their diagnostic values. <i>Lipids in Health and Disease</i> , 2021, 20, 155.	1.2	6
451	Phospholipase D is Dispensable for Epidermal Growth Factor-Induced Chemotaxis. <i>Kobe Journal of Medical Sciences</i> , 2017, 62, E162-E167.	0.2	0
452	Prospective of SNCA in nervous system diseases. , 2017, 3, 10-16.		0
453	Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors. <i>International Review of Movement Disorders</i> , 2021, 2, 1-63.	0.1	0
454	Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases. <i>Frontiers in Neuroscience</i> , 2021, 15, 806260.	1.4	11
456	Therapeutics in the Pipeline Targeting α -Synuclein for Parkinson's Disease. <i>Pharmacological Reviews</i> , 2022, 74, 207-237.	7.1	39
457	A Mechanistic Overview of the Cellular Pathology and Prion-Like Propagation of α -Synuclein in Parkinson's Disease: A Narrative Review. , 2022, 6, .		0
458	Insulin-like growth factor 2 and autophagy gene expression alteration arise as potential biomarkers in Parkinson's disease. <i>Scientific Reports</i> , 2022, 12, 2038.	1.6	16
459	Leukotriene Signaling as a Target in α -Synucleinopathies. <i>Biomolecules</i> , 2022, 12, 346.	1.8	5
460	Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 805087.	1.4	13
461	The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders. <i>Current Neuropharmacology</i> , 2023, 21, 183-201.	1.4	6
462	Small but Mighty "Exosomes, Novel Intercellular Messengers in Neurodegeneration. <i>Biology</i> , 2022, 11, 413.	1.3	15
463	Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 174.	2.4	45
464	Emerging Potential of Exosomal Non-coding RNA in Parkinson's Disease: A Review. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 819836.	1.7	10
465	Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications. <i>Cells</i> , 2022, 11, 1279.	1.8	11
466	Rotenone induces regionally distinct α -synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice. <i>Neurobiology of Disease</i> , 2022, 167, 105685.	2.1	17
467	Identification of Novel Biomarkers in Platelets for Diagnosing Parkinson's Disease. <i>European Neurology</i> , 2022, 85, 122-131.	0.6	2

#	ARTICLE	IF	CITATIONS
468	Synucleinopathies. , 2014, , 149-175.		0
477	The Role of Extracellular Matrix Components in the Spreading of Pathological Protein Aggregates. <i>Frontiers in Cellular Neuroscience</i> , 2022, 16, 844211.	1.8	7
478	Ultrastructural and biochemical classification of pathogenic tau, $\hat{\pm}$ -synuclein and TDP-43. <i>Acta Neuropathologica</i> , 2022, 143, 613-640.	3.9	22
479	Raman Spectroscopy Study of Skin Biopsies from Patients with Parkinsonâ€™s Disease: Trends in Alpha-Synuclein Aggregation from the Amide I Region. <i>Applied Spectroscopy</i> , 2022, 76, 1317-1328.	1.2	3
480	$\hat{\pm}$ -Synuclein Impacts on Intrinsic Neuronal Network Activity Through Reduced Levels of Cyclic AMP and Diminished Numbers of Active Presynaptic Terminals. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, .	1.4	2
481	Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 3139.	1.0	3
482	The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged Humans. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
483	Polarized $\hat{\pm}$ -synuclein trafficking and transcytosis across brain endothelial cells via Rab7-decorated carriers. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	12
484	The Common Cellular Events in the Neurodegenerative Diseases and the Associated Role of Endoplasmic Reticulum Stress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5894.	1.8	15
486	Exogenous human $\hat{\pm}$ -Synuclein acts in vitro as a mild platelet antiaggregant inhibiting $\hat{\pm}$ -thrombin-induced platelet activation. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
487	$\hat{\pm}$ -Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	3
488	Microglia Phenotypes in Aging and Neurodegenerative Diseases. <i>Cells</i> , 2022, 11, 2091.	1.8	76
489	Gene-Based Therapeutics for Parkinsonâ€™s Disease. <i>Biomedicines</i> , 2022, 10, 1790.	1.4	3
490	Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2022, 269, 6386-6394.	1.8	10
491	Lysosomal exocytosis releases pathogenic $\hat{\pm}$ -synuclein species from neurons in synucleinopathy models. <i>Nature Communications</i> , 2022, 13, .	5.8	28
492	Spreading of alpha-synuclein between different cell types. <i>Behavioural Brain Research</i> , 2023, 436, 114059.	1.2	6
493	Oligomeropathies, inflammation and prion protein binding. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	3
494	Neuroinflammation and Parkinsonâ€™s Diseaseâ€™ From Neurodegeneration to Therapeutic Opportunities. <i>Cells</i> , 2022, 11, 2908.	1.8	28

#	ARTICLE	IF	CITATIONS
495	LRP1 is a neuronal receptor for α -synuclein uptake and spread. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	26
496	Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
497	Pathogenesis of α -Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14753.	1.8	14
498	Time-dependent alterations in the rat nigrostriatal system after intrastriatal injection of fibrils formed by α -Syn and tau fragments. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
499	Multiple system atrophy: α -Synuclein strains at the neuron-oligodendrocyte crossroad. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	8
500	Huntingtin and Other Neurodegeneration-Associated Proteins in the Development of Intracellular Pathologies: Potential Target Search for Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15533.	1.8	2
501	The Hidden Cell-to-Cell Trail of α -Synuclein Aggregates. <i>Journal of Molecular Biology</i> , 2023, 435, 167930.	2.0	9
502	Unconventional secretion of α -synuclein mediated by palmitoylated DJA1C5 oligomers. <i>ELife</i> , 0, 12, .	2.8	5
503	Quantitative Seed Amplification Assay: A Proof-of-Principle Study. <i>Journal of Physical Chemistry B</i> , 2023, 127, 1735-1743.	1.2	5
504	Cognitive heterogeneity in Parkinson's disease: A mechanistic view. <i>Neuron</i> , 2023, 111, 1531-1546.	3.8	10
505	Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α -Synuclein in Parkinson's Disease. <i>Biomedicines</i> , 2023, 11, 1187.	1.4	5